Fernand Labrie
Publications
Page 1 of 8, showing 50 records out of 368 total, starting on record 1, ending on 50
| Publication | Category | Year |
|---|---|---|
| 72. van der Kwast, T.H., Têtu, B., Candas, B., Gomez, J.-L., Cusan, L., Labrie, F. (1999) Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology, 53: 523-529. | Prostate Cancer | 1999 |
| 71. van der Kwast, T.H., Labrie, F., Têtu, B. (1999) Prostatic intraepithelial neoplasia and endocrine manipulation. Eur. Urol., 35: 508-510. | Prostate Cancer | 1999 |
| 70. van der Kwast, T.H., Labrie, F., Têtu, B. (1999) Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Hum. Pathol., 30: 1503-1507. | Prostate Cancer | 1999 |
| 80. van der Kwast, T., Têtu, B., Suburu, E.R., Gomez, J., Lemay, M., Labrie, F. (1998) Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. J. Pathol., 186: 406-409. | Prostate Cancer | 1998 |
| 301. Tremblay, Y., Bélanger, A., Lacoste, D., Giasson, M., Labrie, F. (1984) Selective inhibition of spermatogenesis in the presence of normal libido following combined treatment with an LHRH agonist and testosterone in the dog. Contraception, 30: 585-598. | Prostate Cancer | 1984 |
| 300. Tremblay, Y., Bélanger, A., Labrie, F., Frenette, G., Dubé, J.Y., Tremblay, R.R. (1984) Characteristics of the inhibitory effect of chronic treatment with an LHRH agonist on testicular steroidogenesis in the dog. Prostate, 5: 631-638. | Prostate Cancer | 1984 |
| 317. Tolis, G., Ackman, D., Stellos, A., Mehta, A., Labrie, F., Fazekas, A.T.A., Comaru-Schally, A.M., Schally, A.V. (1982) Tumor growth inhibition in patients with prostatic caricnoma treated with luteinizing hormone-releasing hormone agonists. Proc. Natl. Acad. Sci. USA, 79: 1658-1662. | Prostate Cancer | 1982 |
| 198. Têtu, B., Labrie, F., Dupont, A., Monfette, G. (1989) Histopathologic effect of combination therapy on normal prostate and prostatic adenocarcinoma, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, Exerpta Medica ICS 841, pp 63-76. | Prostate Cancer | 1989 |
| 228. St-Arnaud, R., Poyet, P., Walker, P., Labrie, F. (1988) Androgens modulate epidermal growth factor receptor levels in the rat ventral prostate. Mol. Cell. Endocrinol., 56: 21-27. | Prostate Cancer | 1988 |
| 270. St-Arnaud, R., Lachance, R., Kelly, S.J., Bélanger, A., Dupont, A., Labrie, F. (1986) Loss of luteinizing hormone (LH) bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen. Clin. Endocrinol. (Oxf.), 24: 21-30. | Prostate Cancer | 1986 |
| 269. St-Arnaud, R., Lachance, R., Dupont, A., Labrie, F. (1986) Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and Flutamide in patients with cancer of the prostate. Clin. Invest. Med., 9: 215-221. | Prostate Cancer | 1986 |
| 268. St-Arnaud, R., Lachance, R., Dupont, A., Labrie, F. (1986) Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-treated patients treated with an LH-releasing hormone agonist and antiandrogen. J. Clin. Endocrinol. Metab., 63: 297-302. | Prostate Cancer | 1986 |
| 248. Soret, Y., Verine, J.L., Daver, A., Labrie, F. (1987) Levels of intraprostatic androgen receptors and intraprostatic testosterone following orchiectomy with or without addition of an antiandrogen (Flutamide) in the treatment of advanced prostatic cancer. J. Drug Dev., 1: 23-25. | Prostate Cancer | 1987 |
| 247. Soret, J.Y., Verine, J.L., Daver, A., Labrie, F. (1987) Comparative results of the variations in intraprostatic androgen levels and androgen receptors following pulpectomy with or without an antiandrogen (Flutamide) in the treatment of advanced prostate cancer, in: Murphy, G.P., Khoury, S., Kreiss, R., Chatelain, C. et Denis, L., eds: Prostate Cancer Research, Endocrine Treatment and Histopathology. Progress in Clinical and Biological Research, New York, Alan R. Liss Inc., pp 77. | Prostate Cancer | 1987 |
| 267. Simard, J., Luthy, I., Guay, J., Bélanger, A., Labrie, F. (1986) Characteristics of interaction of the antiandrogen Flutamide with the androgen receptor in various target tissues. Mol. Cell. Endocrinol., 44: 261-270. | Prostate Cancer | 1986 |
| 227. Simard, J., Labrie, C., Hubert, J.-F., Labrie, F. (1988) Modulation by sex steroids and [D-Trp6, des-Gly-NH210]LHRH ethylamide of a subunit and LH? mRNA levels in the rat anterior pituitary gland. Mol. Endocrinol., 2: 775-784. | Prostate Cancer | 1988 |
| 329. Séguin, C., Cusan, L., Bélanger, A., Kelly, P.A., Labrie, F., Raynaud, J.P. (1981) Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat. Mol. Cell. Endocrinol., 21: 37-41. | Prostate Cancer | 1981 |
| 328. Séguin, C., Bélanger, A., Cusan, L., Pelletier, G., Reeves, J.J., Lefebvre, F.A., Kelly, P.A., Labrie, F. (1981) Relative importance of the adenohypophyseal and gonadal sites of inhibitory action of LHRH agonists. Biol. Reprod., 24: 889-901. | Prostate Cancer | 1981 |
| 4723. Samson, M., Labrie, F., Luu-The, V. (2010) Sequential transformation of 4-androstenedione into dihydrotestosterone in prostate carcinoma (DU-145) cells indicates that 4-androstenedione and not testosterone is the substrate of 5alpha-reductase. Horm Mol Clin Invest. 1: 67-72. | Prostate Cancer | 2010 |
| 225. Rousseau, L., Dupont, A., Labrie, F., Couture, M. (1988) Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen Flutamide with medical (LHRH agonist) or surgical castration. Arch. Sex. Behav., 17: 87-98. | Prostate Cancer | 1988 |
| 226. Rousseau, L., Dupont, A., Labrie, F., Couture, M. (1988) Sexuality and antihormonal therapy in prostate cancer, in: Eicher, W. et Kockott, G., eds: Sexology, Berlin, Springer-Verlag, pp 290-303. | Prostate Cancer | 1988 |
| 316. Resko, J., Bélanger, A., Labrie, F. (1982) Effects of chronic treatment with a potent LHRH agonist on serum LH and steroid levels in the male rhesus monkey. Biol. Reprod., 26: 378-384. | Prostate Cancer | 1982 |
| 279. Raynaud, J.P., Moguilewsky, M., Tournemine, C., Pottier, J., Coussedière, D., Salmon, J., Husson, J.M., Bertagna, C., Tremblay, D., Pendyala, L., Brisset, J.M., Vallancien, G., Serment, G., Navratil, N., Dupont, A., Labrie, F. (1985) Pharmacology and clinical studies with RU23908 (Anandron). EORTC Genitourinary Group Monograph 2, Part A, in: Schroeder, F.H. et Richards, B., eds: Therapeutic Principles Metastatic Protastic Cancer, New York, Alan R. Liss Inc., pp 99-120. | Prostate Cancer | 1985 |
| 266. Raynaud, J.P., Coussedière, D., Moguilewsky, M., Pottier, J., Labrie, F. (1986) Cancer de la prostate: bases biologiques pour l'emploi d'un antiandrogène dans le traitement. Bulletin du Cancer, 73: 36-46. | Prostate Cancer | 1986 |
| 299. Raynaud, J.P., Bonne, C., Moguilewsky, M., Lefebvre, F.A., Bélanger, A., Labrie, F. (1984) The pure antiandrogen, RU23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review. Prostate, 5: 299-311. | Prostate Cancer | 1984 |
| 341. Raynaud, J.P., Bonne, C., Bouton, M.M., Lagacé, L., Labrie, F. (1979) Action of a non -steroidal anti -androgen, RU23908, in peripheral and central tissues. J. Steroid Biochem., 11: 93-99. | Prostate Cancer | 1979 |
| 278. Poyet, P., Labrie, F. (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol. Cell. Endocrinol., 42: 283-288. | Prostate Cancer | 1985 |
| 265. Poyet, P., Gagné, B., Lavoie, M., Labrie, F. (1986) Characteristics of the ?-adrenergic receptor in the rat ventral prostate using [125I]cyanopindolol. Mol. Cell. Endocrinol., 48: 59-67. | Prostate Cancer | 1986 |
| 264. Poyet, P., Gagné, B., Labrie, F. (1986) Characteristics of the ?-adrenergic stimulation of adenylate cyclase activity in rat ventral prostate and its modulation by androgens. Prostate, 9: 237-245. | Prostate Cancer | 1986 |
| 224. Plante, M., Lapointe, S., Labrie, F. (1988) Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. J. Steroid Biochem., 31: 61-64. | Prostate Cancer | 1988 |
| 197. Pinault, S., Gagnon, J., Monfette, G., Têtu, B., Dupont, A., Labrie, F. (1989) Transrectal ultrasound evaluation of local disease in prostate cancer patients treated with the combination therapy, in: Labrie, F., Lee, F. et Dupont, A., eds: Early State Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 53-62. | Prostate Cancer | 1989 |
| 277. Perez, C.A., Fair, W.R., Ihde, D.C., Labrie, F. (1985) Cancer of the prostate, in: De Vita, V.T., Hellman, S. et Rosenberg, C., eds: Cancer: Principles and Practice of Oncology, Philadelphia, J.P. Lippincott, pp 929-964. | Prostate Cancer | 1985 |
| 4726. Pelletier, G., Luu-The, V., Tetu, B., Labrie, F. (1999) Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem Cytochem., 47: 731-738. | Prostate Cancer | 1999 |
| 78. Pelletier, G., Luu-The, V., Huang, X.F., Lapointe, H., Labrie, F. (1998) Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin. J. Urol., 160: 577-582. | Prostate Cancer | 1998 |
| 223. Pelletier, G., Labrie, C., Simard, J., Duval, M., Martinoli, M.G., Zhao, H., Labrie, F. (1988) Effects of sex steroids on regulation of the levels of C1 peptide of rat prostatic steroid-binding protein mRNA evaluated by in situ hybridization. J. Mol. Endocrinol., 1: 213-223. | Prostate Cancer | 1988 |
| 337. Pelletier, G., Cusan, L., Bélanger, A., Séguin, C., Kelly, P.A., Labrie, F. (1980) Further studies on the inhibitory effects of [D-Ala6, des-Gly-NH210]LHRH ethylamide on spermatogenesis and steroidogenesis in the rat: Reversibility and effect of androgen administration. J. Androl., 1: 171-181. | Prostate Cancer | 1980 |
| 345. Pelletier, G., Cusan, L., Auclair, C., Kelly, P.A., Désy, L., Labrie, F. (1978) Inhibition of spermatogenesis in the rat by treatment with [D-Ala6, des-Gly-NH210]LHRH ethylamide. Endocrinology, 103: 641-643. | Prostate Cancer | 1978 |
| 222. Moorjani, S., Dupont, A., Labrie, F., Lupien, P.J., Gagné, C., Brun, D., Giguère, M., Bélanger, A., Cusan, L. (1988) Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen and combination treatment with LHRH agonist and Flutamide. J. Clin. Endocrinol. Metab., 66: 314-322. | Prostate Cancer | 1988 |
| 246. Moorjani, S., Dupont, A., Labrie, F., Lupien, P.J., Brun, D., Gagné, C., Giguère, M., Bélanger, A. (1987) Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostate cancer. Metabolism, 36: 244-250. | Prostate Cancer | 1987 |
| 196. Monfette, G., Dupont, A., Pinault, S., Gagnon, J., Boivin, J.C., Têtu, B., Labrie, F. (1989) Advantages of downstaging local prostate cancer by 3-month combination therapy prior to radical prostatectomy, in Fourth International Symposium on Transrectal Ultrasound in the Diagnosis and Management of Prostate Cancer, New York, Alan R. Liss Inc., pp 255-261. | Prostate Cancer | 1989 |
| 195. Monfette, G., Dupont, A., Labrie, F. (1989) Temporary combination therapy with Flutamide and Tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 41-42. | Prostate Cancer | 1989 |
| 221. Marchetti, B., Poulin, R., Plante, M., Labrie, F. (1988) Castration levels of plasma testosterone have potent stimulatory effects on androgen-sensitive parameters in the rat prostate. J. Steroid Biochem., 31: 411-419. | Prostate Cancer | 1988 |
| 220. Marchetti, B., Labrie, F. (1988) Characteristics of Flutamide action on prostatic and testicular functions in the rat. J. Steroid Biochem., 29: 691-698. | Prostate Cancer | 1988 |
| 298. Marchetti, B., Labrie, F. (1984) Further characterization of the direct inhibitory effect of LHRH agonists at the testicular level in the rat. J. Steroid Biochem., 20: 339-342. | Prostate Cancer | 1984 |
| 4699. Ma, C., Yoshioka, M., Boivin, A., Gan, L, Takase, Y, Labrie, F., St-Amand, J. (2009) Atlas of dihydrotestosterone actions on the transcriptome of prostate in vivo. The Prostate, 69: 293-316 | Prostate Cancer | 2009 |
| 219. Luthy, I.A., Bégin, D.J., Labrie, F. (1988) Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J. Steroid Biochem., 31: 845-852. | Prostate Cancer | 1988 |
| 245. Luthy, I., Labrie, F. (1987) Development of androgen resistance in mouse mammary tumor cells can be prevented by the antiandrogen flutamide. Prostate, 10: 89-94. | Prostate Cancer | 1987 |
| 218. Luthy, I., Bégin, D., Labrie, F. (1988) Mediation by the androgen receptor of the stimulatory and antiandrogenic actions of 17?-estradiol on the growth of androgen-sensitive Shionogi mammary carcinoma cells in culture. Endocrinology, 123: 1418-1424. | Prostate Cancer | 1988 |
| 315. Lefebvre, F.A., Séguin, C., Bélanger, A., Caron, S., Sairam, M.R., Raynaud, J.P., Labrie, F. (1982) Combined long-term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat. Prostate, 3: 569-578. | Prostate Cancer | 1982 |
| 297. Lefebvre, F.A., Bélanger, A., Pelletier, G., Labrie, F. (1984) Recovery of gonadal functions in the adult male rat following cessation of 5-month daily treatment with an LHRH agonist. J. Androl., 5: 181-192. | Prostate Cancer | 1984 |